. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25;71(22):1770-5. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on Primary Papers and News

  1. It would be appropriate to try doing a trial of IGF-1 BP3 (Iplex) at a higher dose. As ALS patients, many of us do not have two years to waste on stupidity. I used Iplex briefly before the lawsuit rendered it unavailable. My "anecdotal" evidence supported slight improvement in a short period of time. Worth a shot when it comes to people waiting to die, isn't it?

    View all comments by Deborah Gattoni